TSX-V: ERG
LAVAL, QC, Nov. 11, 2016
/CNW Telbec/ - Ergoresearch Ltd ("Ergoresearch" or "the
Company") announces that it has obtained approval from the TSX
venture Exchange in order to proceed with a normal course issuer
bid.
Therefore, for a twelve month period beginning on November 11 2016 and ending on November 10 2017, Ergoresearch will be authorized
to acquire, from time to time and when it deems it appropriate, up
to a maximum of 3,625,452 common shares, representing approximately
5% of the issued and outstanding shares as at November 11, 2016.
The common shares purchased will be cancelled.
As of November 11, 2016,
Ergoresearch had 72,509,040 common shares issued and outstanding.
The Company had purchased 3,813,633 common shares in the twelve
month period that ended on November
10 2016.
Ergoresearch's Board of Director considers that the acquisition
of common shares in the course of this issuer bid may represent a
sound use of the Corporation's funds both for the Corporation and
for its shareholders. Purchases will be made in accordance with TSX
venture Exchange requirements, on the open market through the
facilities of the Exchange. To the knowledge of the Company,
no director, senior officer or other insider of Company currently
intends to sell any common shares under this Bid.
As of today, Ergoresearch reports no significant changes in its
business or its activities.
None of Ergoresearch's directors or senior officers, nor any of
their associates, nor any person acting jointly or in concert with
Ergoresearch, or holding 10% or more of the shares of any class of
shares of Ergoresearch, will receive any direct or indirect benefit
as a result of this Normal Course Issuer Bid other than the
benefits conferred upon all Ergoresearch shareholders.
GMP Securities LP, 145 King Street West, Toronto (Ontario) M5H 1J8, will act as member and
broker in connection with this Bid.
The Normal Course Issuer Bid has been approved by the TSX
Venture Exchange.
About Ergoresearch
Ergoresearch is a Canadian company that designs and
manufactures cutting edge technologies for the orthopedic industry.
The Corporation is a trend-setter in creating custom orthotics and
speciality orthotics for the orthopedics market and holds a
portfolio of patents in the orthopedics field and in human bionics.
The mission of our banner "Équilibre orthèses et biomécanique" is
to keep people active and moving. "ÉQUILIBRE", driven by its
proprietary technologies and the expertise of its professionals,
offers a range of products, treatments and services in order to
relieve pain, restore motor function and optimize performance.
This document is not intended to encourage the purchase of
securities listed on the TSX Venture Exchange. TMX Group and its
affiliates do not endorse or recommend any of the securities
referenced here. Please seek professional advice to evaluate
specific securities.
Forward-looking statements
Certain statements in this Press Release contain forward-looking
statements and information that may entail certain risks related to
uncertainties. Such statements are based on management's
expectations and no assurance can be given that potential future
results or circumstances described in the forward looking
statements will be achieved or will occur, as these statements are
subject to numerous uncertainties and risk factors. Such risk
factors include, but are not limited to, those related to the
Company's ability to finance its activities, competition, ability
to negotiate and maintain partnerships, the market acceptance of
the Company's product, the strength of intellectual property, the
success of research and development programs, the trust invested in
sub-contractors or their core personnel as well as other risks and
uncertainties that are put forth every now and then by the Company
in the documents filed with various Canadian securities and
exchange commissions and made available at
www.sedar.com.
The reader should not give great importance to forward-looking
statements as (i) the results may differ from conclusions,
predictions or projections contained in such forward-looking
statements; and (ii) certain important factors or hypotheses taken
into account in reaching conclusions or the preparation of a
projection or prediction may prove to be incorrect in fact.
These statements are correct only on the date on which they were
written, and Management disclaims any obligation to revise these
statements after any event, circumstance or other situation, except
as required by law. All figures are in Canadian dollars, unless
otherwise specified.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Ergoresearch Ltd